Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment

Oncolytic herpes simplex viruses (oHSVs) have demonstrated efficient lytic replication in human glioblastoma tumors using immunodeficient mouse models, but early-phase clinical trials have reported few complete responses. Potential reasons for the lack of efficacy are limited vector potency and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Joseph W., Hall, Bonnie L., Marzulli, Marco, Shah, Vrusha K., Bailey, Lisa, Chiocca, E. Antonio, Goins, William F., Kohanbash, Gary, Cohen, Justus B., Glorioso, Joseph C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430372/
https://www.ncbi.nlm.nih.gov/pubmed/34553031
http://dx.doi.org/10.1016/j.omto.2021.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430372/
https://www.ncbi.nlm.nih.gov/pubmed/34553031
http://dx.doi.org/10.1016/j.omto.2021.07.009

Ejemplares similares